The iconic rise of Viagra has long been a example of pharmaceutical success, yet its legacy within the broader sector now presents questions about long-term returns . Alternative versions are diminishing market share, prompting worries that betting on companies closely tied to Viagra's previous influence could be a problematic decision , especially